CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Taipei, Taiwan and 112 other locations
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...
Phase 2
Taipei, Taiwan and 43 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Taipei, Taiwan and 121 other locations
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....
Phase 3
Taoyuan, Taiwan and 135 other locations
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Phase 1, Phase 2
Taipei City, Taiwan and 65 other locations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...
Phase 1
Taipei, Taiwan and 43 other locations
and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with N...
Phase 1
Taipei, Taiwan and 8 other locations
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination w...
Phase 1
Taipei, Taiwan and 17 other locations
solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and nec...
Phase 2
Taipei, Taiwan and 9 other locations
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with sele...
Phase 1
Taipei, Taiwan and 12 other locations
Clinical trials
Research sites
Resources
Legal